Summary. We consider a clinical trial with a primary and a secondary endpoint where the secondary endpoint is tested only if the primary endpoint is significant. The trial uses a group sequential procedure with two stages. The familywise error rate (FWER) of falsely concluding significance on either endpoint is to be controlled at a nominal level α. The type I error rate for the primary endpoint is controlled by choosing any α-level stopping boundary, e.g., the standard O'Brien-Fleming or the Pocock boundary. Given any particular α-level boundary for the primary endpoint, we study the problem of determining the boundary for the secondary endpoint to control the FWER. We study this FWER analytically and numerically and find that it is maximized when the correlation coefficient ρ between the two endpoints equals 1. For the four combinations consisting of O'Brien-Fleming and Pocock boundaries for the primary and secondary endpoints, the critical constants required to control the FWER are computed for different values of ρ. An ad hoc boundary is proposed for the secondary endpoint to address a practical concern that may be at issue in some applications. Numerical studies indicate that the O'Brien-Fleming boundary for the primary endpoint and the Pocock boundary for the secondary endpoint generally gives the best primary as well as secondary power performance. The Pocock boundary may be replaced by the ad hoc boundary for the secondary endpoint with a very little loss of secondary power if the practical concern is at issue. A clinical trial example is given to illustrate the methods.
Introduction
Since the pioneering works of Pocock (1977) and O'Brien and Fleming (1979) , group sequential designs have been widely studied and are now commonly employed in clinical trials. Jennison and Turnbull (2000) is a comprehensive reference on this topic. Much of the work on group sequential designs deals with a single endpoint. Jennison and Turnbull (1993) discussed a group sequential design for bivariate endpoints (efficacy and safety). They determined two-sided decision boundaries for the test statistics computed for both endpoints so that if the new treatment is shown to be superior on both endpoints then it is accepted; if it is shown to be inferior on one of the endpoints then it is rejected; otherwise sampling is continued to the next stage. We are interested in the problem of testing null hypotheses on hierarchically ordered endpoints, e.g., a primary and a secondary endpoint. For such endpoints, it is generally required that statistical significance be shown on the primary endpoint before the secondary endpoint can be validly tested (O'Neill, 1997) . Gatekeeping procedures Tamhane, 2007, 2010 ) deal with such endpoints; however, these procedures have been studied only for nonsequential designs. This article studies the problem of testing a primary and a secondary endpoint in a two-stage group sequential setting with the former acting as a gatekeeper for the latter. This problem was originally studied by Hung, Wang, and O'Neill (2007) . While this article was being revised, we received a manuscript by Glimm, Maurer, and Bretz (2010) which addresses the same problem and reaches similar conclusions but does not give explicit analytical results concerning the familywise error rate (FWER) and the primary and secondary critical boundaries as we derive in this article. These two works are completely independent and complementary to each other.
The outline of the article is as follows: Section 2 describes the group sequential procedure (GSP) for the stated problem. Section 3 discusses control of the FWER for this GSP. This section also gives a table of the critical constants using either the O'Brien-Fleming (OF) or the Pocock (PO) boundaries for the primary and secondary endpoints resulting in four different combinations. Two additional combinations that use the OF or the PO boundary for the primary and an ad hoc (AH) boundary for the secondary endpoint are also studied.
This AH boundary is introduced to address a practical concern that is explained in Section 3.2. The powers of these six different boundary combinations are compared in Section 4. Section 5 gives a clinical trial example. Section 6 outlines extensions for future research to deal with unknown correlation coefficient, multiple stages and multiple endpoints. The proofs of all theoretical results are included in Supplementary Materials.
Group Sequential Procedure
Consider a GSP with two stages and a primary and a secondary endpoint. Let n 1 and n 2 be the sample sizes for the two stages. Suppose that the observations on the primary endpoint are i.i.d. N (μ 1 , σ 2 1 ) and those on the secondary endpoint are i.i.d. N (μ 2 , σ 2 2 ). Further suppose that the two endpoints are jointly distributed as bivariate normal with correlation coefficient ρ 0. Hung et al. (2007) considered the problem of testing the null hypotheses H 1 : μ 1 = 0 and H 2 : μ 2 = 0 against one-sided alternatives with H 2 being tested if H 1 is rejected either at the first stage or at the second stage. Thus, the primary endpoint acts as a gatekeeper for the secondary endpoint. The FWER requirement is
for specified α. The standardized cumulative sample means at the two stages are used as the test statistics for both endpoints. Denote by (X 1 , X 2 ) the cumulative test statistics at the two stages for the primary endpoint and (Y 1 , Y 2 ) the corresponding test statistics for the secondary endpoint. Let (c 1 , c 2 ) and (d 1 , d 2 ) denote the corresponding stopping boundaries. We will use the following GSP. In general, X j ∼ N (Δ 1j , 1) and Y j ∼ N (Δ 2j , 1) for j = 1, 2, where
under H i , Δ ij = 0 (i, j = 1, 2). Frequently, we will denote the noncentrality parameters by Δ i = Δ i 1 = γΔ i 2 (i = 1, 2), where
The correlations among (X 1 , X 2 , Y 1 , Y 2 ) are given by 
Any pair of constants, (c 1 , c 2 ), that satisfy this inequality will be referred to as an α-level boundary. For the OF boundary, c 2 = γc 1 , whereas for the PO boundary, c 2 = c 1 .
More generally, we could use the error spending function approach of Lan and DeMets (1983) to calculate the primary boundary (c 1 , c 2 ). Let α(t) be a nondecreasing function defined over t ∈ [0, 1] such that α(0) = 0 and α(1) = α; here t is called the information fraction. Let t 1 = n 1 /(n 1 + n 2 ) and t 2 = 1. Then (c 1 , c 2 ) can be calculated from the following two equations:
For a K-stage GSP (K 2) with equal information in each stage, i.e., t i = i/K (1 i K), an error spending function that approximates the OF boundary is given by (Lan and DeMets, 1983) :
where Φ(·) is the standard normal cdf and z α / 2 is the (1 − α/2)-quantile of the standard normal distribution. Similarly, an error spending function that approximates the PO boundary is given by (Lan and DeMets, 1983) :
These spending functions are used in the example of Section 5.
In conclusion, the FWER control problem is: Given a choice of (c 1 , c 2 ) satisfying equation (4), determine (d 1 , d 2 ) so that equation (1) is satisfied under H 2 . We will assume this configuration, which implies that Δ 1 0 and Δ 2 = 0, throughout the next section.
Choice of the Secondary Boundary
To test multiple hypotheses in a group sequential setup, Tang and Geller (1999) showed that if there exists a GSP to test every intersection hypothesis at level α then application of the closure principle of Marcus, Peritz, and Gabriel (1976) As seen earlier, an α-level GSP of H 1 ∩ H 2 is the same as the GSP of H 1 because of the hierarchical testing of H 1 and H 2 . Therefore, if we use any α-level secondary boundary for testing H 2 conditional on rejecting H 1 , then the overall FWER will be controlled. However, it is possible to use a more liberal secondary boundary by exploiting the dependence of the FWER on the correlation coefficient ρ as calculations in Table 1 shows. The calculations were made using the following expression for FWER under H 2 :
where φ(·) denotes the pdf of the standard normal distribution; also Δ 11 = γΔ 12 = Δ 1 . This expression is obtained by setting Δ 21 = Δ 22 = 0 in the secondary power expression (8). Hung et al. (2007) investigated the choice d 1 = d 2 = z α (where z α is the upper α critical point of the N (0, 1) distribution) as Strategy 1 on the basis that the primary and secondary endpoints are tested in a fixed sequence, and so H 2 can be tested at level α following rejection of H 1 at level α. We show in Proposition 1 that this choice does not control the FWER for all ρ and Δ 1 .
However, for ρ = 1, max Δ 1 FWER > α and thus FWER is not controlled for all ρ and Δ 1 .
To illustrate the results of Proposition 1, we considered the OF boundary for the primary endpoint with α = 0.05 and n 1 = n 2 = n, which uses (c 1 , c 2 ) = (1.678 √ 2, 1.678). Figure 2 shows that this is achieved when Δ 1 = 0, ρ = 1, and d 1 = d 2 = 1.876, which corresponds to α * = 0.0303. Note that this is the PO boundary for α = 0.05. We will show this numerical result analytically in Proposition 3.
In Propositions 2-4 that follow, we study three different combinations of the α-level boundaries: Tang and Geller (1999) it follows that all three boundaries control the FWER. In the first two cases we show that max FWER = α, whereas in the third case we show that max FWER < α. Hence it is possible to use a more liberal (d 1 , d 2 ) boundary with level α > α in the third case. √ 2, 1.678) and n 1 = n 2 .
is an α-level boundary for the primary and secondary endpoints then for ρ = 1, max Δ 1 FWER = α is attained at Δ 1 = 0 and for Δ 1 = 0, max ρ FWER = α is attained at ρ = 1.
Note that this proposition does not show that the global maximum of FWER is attained at Δ 1 = 0 and ρ = 1, which we conjecture to be true but have been unable to prove. However, plots in Figure 
Propositions 2-4 are illustrated by calculations in Table 1 of the secondary boundary (d 1 , d 2 ) that controls the FWER at level α for the two choices of the α-level primary boundary (c 1 , c 2 ) for α = 0.05, n 1 = n 2 = n, and ρ = 0.0(0.2)1.0. For the OF boundary, (c 1 , c 2 ) = (1.678 √ 2, 1.678) and for the PO boundary, (c 1 , c 2 ) = (1.876, 1.876). The same two choices are used for the secondary stopping boundary in the following way: In addition, we considered another boundary to address a referee's practical concern over having the secondary boundary with a level α > α, as shown in Proposition 4. Note that, although the marginal error rate for the secondary endpoint exceeds α, the joint FWER for the primary and secondary endpoints is controlled at α. However, the referee thought that this subtlety may be difficult to explain to clinicians, and in fact suggested that both Table 1 . Thus, the OF1-PO2 and PO1-PO2 combinations satisfy the referee's practical condition; as will be seen in the next section, the OF1-PO2 combination generally gives higher power for both the primary and the secondary endpoint, and is therefore preferred.
For the OF secondary boundary,
, it is possible to have d 2 < z α and still control FWER. If this occurs then we set d 2 = z α and then find the smallest d 1 z α such that max FWER = α is maintained. We refer to this modified boundary as an AH boundary. We computed this secondary boundary for two additional combinations with the OF and PO as the primary boundaries. Note that we did not employ the AH boundary for the primary endpoint in our study. This gave a total of six combinations of the primary and secondary boundaries.
The following observations can be made from the numerical results in Table 1. (1) The value of Δ 1 that maximizes FWER for fixed ρ is a decreasing function of ρ. 
Power
There are two powers of interest: (i) primary power (Power 1 ), the probability of rejecting a false H 1 , is just the power of GSP for a single endpoint that has been studied previously in the literature; and (ii) secondary power (Power 2 ), the probability of rejecting a false H 2 . Note that Power 1 Power 2 for the same Δ ij (i, j = 1, 2). The overall power for rejecting H 1 and H 2 when both are false or only H 2 is false is just the secondary power.
Consider an arbitrary configuration with Δ i 0 (i = 1, 2). The primary power is given by
where X j ∼ N (Δ 1j , 1) (j = 1, 2) with corr(X 1 , X 2 ) = γ. Noting that the conditional distribution of X 2 given U = X 1 − Δ 11 = u is N (Δ 12 + γu, 1 − γ 2 ), we get Power 1 = Φ(−c 1 + Δ 11 )
The secondary power is given by
where
, 1) (j = 1, 2) have the correlation structure shown in equation (4). In the first term, the conditional distribution of Y 1 given U = X 1 − Δ 11 = u is N (Δ 21 + ρu, 1 − ρ 2 ). Similarly, in the second term, the conditional distribution of (X 1 , Y 2 ) given U = X 2 − Δ 12 = u is bivariate normal with mean vector (Δ 11 + γu, Δ 22 + ρu) and covariance matrix 1 ργ
i.e., conditional on U = X 2 − Δ 12 = u, X 1 and Y 2 are independent N (Δ 11 + γu, 1 − γ 2 ) and N (Δ 22 + ρu, 1 − ρ 2 ), respectively. Using these results we get
We studied the primary and secondary powers for the six combinations of the boundaries for which Table 1 is given. The powers were numerically evaluated (not simulated) using equations (7) and (8). It can be shown that the OF boundary is uniformly (in Δ 1 ) more powerful in terms of primary power than the PO boundary. Jennison has proved this result more generally for any two α-level boundaries, (c 1 , c 2 ) and (c 1 , c 2 ): if the test statistics have the monotone likelihood ratio distribution property then (c 1 , c 2 ) is uniformly more powerful than (c 1 , c 2 ) if c 1 > c 1 , c 2 < c 2 .
The secondary power is more complicated to study because it depends on the particular combination of the boundaries used for the primary and secondary endpoints as well as the values of ρ and Δ ij . The plots of secondary powers as functions of Δ 1 for the six combinations of the boundaries studied in Table 1 for α = 0.05, n 1 = n 2 , ρ = 0.4, and Δ 2 = 1, 2, 3 are given in Figures 4-6; the patterns of the power functions are similar for other values of ρ and hence are not shown here. These figures show that generally the combination of the OF boundary for the primary endpoint and the PO boundary for the secondary endpoint (the OF1-PO2 combination) gives the highest secondary power. With the OF1-PO2 combination, we have d 1 , d 2 1.645, so the practical concern raised earlier is not an issue. The OF1-AH2 has secondary power very similar to that of the OF1-PO2 combination, because their critical boundaries are similar. The reason that the secondary powers of the OF1-PO2 and OF1-AH2 combinations are close is because their critical boundaries are close. For ρ = 0.4, the OF1-PO2 boundaries are (c 1 = 1.678 √ 2, c 2 = 1.678) and (d 1 = 1.686, d 2 = 1.686) whereas the OF1-AH2 boundaries are (c 1 = 1.678 √ 2, c 2 = 1.678) and (d 1 = 1.714, d 2 = 1.645). The power curves show that, for large Δ 1 , any combination using OF2 is markedly worse than those using either PO2 or AH2. This is explained by the fact that when Δ 1 is large, there is a high chance of rejecting H 1 at the first look; so OF2 presents a higher threshold for the secondary endpoint to exceed at that look. Also note that for large Δ 1 , the secondary power of OF1-OF2 is lower than that of PO1-OF2, which in turn is uniformly dominated by OF1-PO2 for all Δ 1 as well as the three values of Δ 2 that were studied. Thus, PO1-OF2 is not a contender. OF1-OF2 combination has a slight edge for small Δ 1 . However, if OF1-OF2 is disqualified based on the referee's practical concern then OF1-AH2 may be preferred for small Δ 1 as well.
In looking at these plots, one may be intrigued by the fact that the secondary power of each combination of boundaries decreases with Δ 1 for large Δ 1 (Δ 1 2) for fixed Δ 2 . The reason is that the probability of rejecting H 1 at the first stage increases as Δ 1 increases. Therefore, for large Δ 1 , H 2 gets only one chance to be tested at stage 1 and so the secondary power decreases as Δ 1 increases, approaching P (Y 1 > d 1 ) as Δ 1 → ∞. On the other hand, for small Δ 1 , H 2 gets two chances to be tested; therefore, the secondary power increases as Δ 1 increases.
Example
To illustrate the methods discussed in this article, we consider the CAPTURE study (Simoons et al. 1997) in which a randomized trial was conducted to compare abciximab with placebo for coronary intervention in refractory unstable angina. It was planned to enroll 1400 patients to placebo and abciximab in equal proportions. The primary endpoint was a composite of death, myocardial infarction, or urgent intervention for treatment of recurrent ischemia, within 30 days of randomization. From previous studies in this patient population, the placebo event rate was estimated to be 15%. The investigators wished to provide good power to detect a 5% reduction in the event rate for the abciximab arm. With a sample size of 1400, a single-look design has 81% power to detect this treatment effect, using a one-sided test at the α = 0.025 level of significance. The trial was, however, designed for a group sequential test with three equally spaced looks and OF-type stopping boundaries derived from the error spending function (5). Because of the possibility of early stopping, there is a power loss of about 1% with the group sequential design relative to the corresponding fixed sample design. For illustrative purposes we will ignore the possibility of early stopping at the first look and consider this to be a two-look design. This is a reasonable approximation because this error spending function yields an extremely conservative stopping boundary at the first look with a negligible chance of early stopping even under the alternative hypothesis of a 5% drop in the event rate.
The main secondary endpoint for this trial was death or myocardial infarction within 30 days of randomization. Although in the actual trial there was no formal testing strategy to protect the FWER of the two endpoints, we will consider two such strategies here. Under Strategy 1, we prespecify in the protocol that the secondary endpoint will be tested only if the null hypothesis for the primary endpoint is rejected; moreover, it will be tested at the same look and with the same spending function as the primary endpoint. This may be considered a conservative strategy because the secondary endpoint will face the same conservative OF-type stopping boundary as the primary endpoint. Suppose, however, that abciximab is expected to reduce the risk for the secondary endpoint to a lesser degree than that for the primary endpoint. It might then be advantageous to consider a more aggressive Strategy 2 in which the type I error for the secondary endpoint is spent at a faster rate, resulting in a less demanding early stopping boundary at the first look. For example, one might prespecify the use of PO-type stopping boundary derived from the error spending function (6) for the secondary endpoint.
Let π 1e and π 1c denote the true event rates for the experimental (abciximab) and control (placebo) arms, respectively, with respect to the primary endpoint. Let π 2e and π 2c be the corresponding true event rates for the secondary endpoint. Define μ i = π ic − π ie , i = 1, 2. Let n 1 and n 2 be the sample sizes per arm at the two stages and N = 2(n 1 + n 2 ) be the planned maximum total sample size. The Wald statistics for the primary and secondary endpoints at the interim look are given by
where (π
ie ) denotes the maximum likelihood estimate of (π ic , π ie ) at the interim look and
The Wald statistics for the primary and secondary endpoint at the final look are given by
ie ) denotes the maximum likelihood estimate of (π ic , π ie ) at the final look and
Applying the large sample results of Jennison and Turnbull (2000, Chapter 3) , the above sequentially computed Wald statistics have independent increments, so that (X 1 , X 2 , Y 1 , Y 2 ) have the same distributional properties as the corresponding random variables defined in Section 2. We may thus avail of the results presented in Section 3 for controlling the FWER. No data are available to estimate the correlation coefficient ρ, so we will assume the least favorable configuration ρ = 1.
In the CAPTURE study, an interim analysis was performed after data were available on 1050 subjects out of a planned 1400 subjects. Thus, the relevant information fractions are t 1 = 1050/1400 = 0.75 and t 2 = 1400/1400 = 1. We compute the stopping boundary (c 1 , c 2 ) from the spending function (5) by solving P H 1 (X 1 > c 1 ) = α 1 (t 1 ) and P H 1 (X 1 > c 1 )
For Strategy 1 we set (c 1 , c 2 ) = (d 1 , d 2 ) . For α = 0.025, we obtain (c 1 , c 2 ) = (2.340, 2.012). (The classical OF boundary would be (c 1 , c 2 ) = (2.327, 2.015).)
For Strategy 2, we compute the stopping boundary (d 1 , d 2 ) from the spending function (6) by solving for the placebo arm and 55/518 (10.6%) for the abciximab arm. Although no data were available for the secondary endpoint, we extrapolated from the published results of Simoons et al. (1997) to give 44/532 (8.3%) for the placebo arm and 26/518 (5%) for the abciximab arm. The test statistics are displayed in Table 2 and the stopping boundaries are displayed in Table 3 .
The trial was terminated at the interim look because the test statistic X 1 for the primary endpoint crossed its early stopping boundary c 1 . To formally claim statistical significance in the product label for the secondary endpoint, the test statistic Y 1 would have to cross its early stopping boundary d 1 . It is seen that the secondary statistic does not cross its early stopping boundary under Strategy 1, but it does so under Strategy 2. Thus, depending on what was prespecified in the protocol, the investigators might or might not be allowed to claim statistical significance for the secondary endpoint.
Extensions
The scope of this work is somewhat limited. First, we have considered only one-sided tests on two endpoints with two stages. Second, the data on the primary and secondary endpoints are assumed to be bivariate normal with known standard deviations and a nonnegative correlation coefficient that is either assumed to be known or treated as a nuisance parameter with the FWER being maximized with respect to it to determine the critical boundaries for the endpoints. These limitations are in part dictated by the analytical and computational difficulties involved. Given the practical importance of this problem, we expect that this work will serve as a springboard for further extensions, some of which are outlined later.
Unknown Correlation
The plots of FWER in Figures 4-6 and the critical constants tabulated in Table 1 show that max Δ 1 FWER is an increasing function of ρ with ρ = 1 being the least favorable case. If an upper bound on ρ can be specified then it can be used to find a more powerful boundary for the secondary endpoint than the conservative boundary corresponding to ρ = 1. A practical approach to this problem would be to use the upper limit of a one-sided confidence interval on ρ estimated from the data after stage 1 to find the stage 2 boundary with a suitable adjustment to the required FWER to take into account the error probability of the true ρ exceeding the upper confidence limit. The ideas from Berger and Boos (1994) can be used in this context as follows. Let ρ * be a (1 − ε)-level upper confidence limit on ρ (e.g., calculated using Fisher's large sample arctan hyperbolic transformation), i.e., P (ρ ρ * ) = 1 − ε. Then, using the property that max Δ 1 FWER(Δ 1 , ρ) is an increasing function of ρ, the overall maximum FWER can be written as follows. Let Δ * 1 (ρ) be the value of Δ 1 that maximizes FWER(Δ 1 , ρ) for fixed ρ. Then
(1), 1) × ε. We want to determine the smallest possible (d 1 , d 2 ) (to maximize the power) subject to the earlier expression being α. This problem can be solved iteratively on a computer. For illustration, suppose we choose the PO boundary for the secondary endpoint, i.e., 
Multiple Stages
In this article, we have restricted to a GSP with two stages. However, most practical applications involve more than two stages. Restricting still to two endpoints but K 2 stages, denote the cumulative standardized test statistics for the primary and secondary endpoints at the kth stage by X k and Y k , respectively. The FWER control problem is to determine the critical boundaries (c 1 , c 2 Tang and Geller (1999) it follows that the FWER will be controlled at level α. However, a more detailed analysis can be carried out to sharpen the secondary boundary as a function of ρ as was done for K = 2 stages. It would be useful to develop a software that would compute these boundaries for any choice of the primary boundary, e.g., from the class of boundaries based on error spending functions of Lan and DeMets (1983) and Wang and Tsiatis (1987) .
Multiple Endpoints
Multiple endpoints are of less practical interest than multiple stages, but it may be of interest to study three ordered endpoints (primary, secondary, and tertiary It is easy to show that if all three boundaries are α-level then the FWER will be controlled. A challenging problem is how the knowledge (or estimates) of the correlation coefficients between the three endpoints can be used to sharpen the boundaries for the secondary and tertiary endpoints. This problem is complicated by the fact that there are three correlation coefficients.
Finally, we mention another extension for K = 2 in which one may continue sampling to the second stage and test H 2 if H 1 is rejected but H 2 is not rejected at the first stage, effectively offering a second chance for the secondary endpoint to be tested.
Supplementary Materials
The Web Appendix referenced in Section 1, which gives the proofs of all propositions, is available under the Paper Information link at the Biometrics website http://www. biometrics.tibs.org.
